Stevanato Group S.p.a. · NYSE:STVN
Stevanato — Q3 2025 Earnings Presentation
21 slides from Stevanato's earnings presentation, Nov 6, 2025
Slide 1: Stevanato Group Q3 2025 Financial Results
Stevanato Group Q3 2025 Financial Results November 6, 2025 Exhibit 99.1
Slide 2: Safe Harbor Statement
Q3 2025 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato
Slide 3: Stevanato Group Earnings Call
Q3 2025 Financial Results Stevanato Group Q3 2025 Financial Results Earnings Call Franco Stevanato Chairman & CEO Marco Dal Lago CFO Lisa Miles CCO and IR
Slide 4: Franco Stevanato, Chairman & Chief Executive Officer
Franco Stevanato Chairman & Chief Executive Officer Q3 2025 Financial Results
Slide 5: Top-line Growth, Record Mix of HVS, and Continued Margin Expansion
Q3 2025 Financial Results Top-line Growth, Record Mix of HVS, and Continued Margin Expansion Q3 2025 results exceeded our expectations Benefited from favorable timing of some product shipments in the BDS Segment, previously scheduled to occur in Q4 2025 Compared with Q3 2024, faced headwinds from FX
Slide 6: Engineering Segment: Meaningful Operational Progress on Optimization Plan
Q3 2025 Financial Results Engineering Segment: Meaningful Operational Progress on Optimization Plan Squarely focused on execution and meeting customer commitments Yielded operational improvements, but financial performance below our expectations Returning Segment to historical performance levels wil
Slide 7: Latina, Italy and Fishers (IN), U.S. site updates
Q3 2025 Financial Results Latina, Italy Scaling commercial production for high-value Nexa® PFS Installation of PFS manufacturing lines and validation activities will continue into 2026, as planned Preparing for the next phase of RTU cartridge production, powered by our new RTU 400 EZ-fill® cartridge
Slide 8: Marco Dal Lago, Chief Financial Officer
Marco Dal Lago Chief Financial Officer Q3 2025 Financial Results
Slide 9: Financial Highlights
Q3 2025 Financial Results Q3 2025: Financial Highlights __________ All comparisons refer to Q3 2024 unless otherwise specified. * Adjusted operating profit margin, adjusted net profit, adjusted DEPS, adjusted EBITDA, adjusted EBITDA margin, are non-GAAP financial measures. Please refer to slides 16
Slide 10: Segment Trends
Q3 2025 Financial Results Q3 2025: Segment Trends 233 Q3 2024 267 Q3 2025 Revenue increased 14% (17% at cc), driven by growth in HVS. Outperformed expectations driven by ~€10M in revenue from product shipments previously expected to occur in Q4 2025 Record-level of HVS revenue of €147.9 M, underpinn
Slide 11: Balance Sheet and Cash Flow Items in Q3 2025
Q3 2025 Financial Results Balance Sheet and Cash Flow Items In Q3 2025 At Quarter Ended September 30, 2025 € 0.3M Free Cash Flow* € 333.0M Net Debt* € 113.3M Total Cash and Cash Equivalents € 54.9M CapEx* € 47.2M Net Cash Generated from Operations __________ *Net Debt, CapEx, Free Cash Flow are non-
Slide 12: Maintaining Fiscal 2025 Guidance
Q3 2025 Financial Results Maintaining Fiscal 2025 Guidance __________ *Adjusted operating profit margin, adjusted net profit, adjusted DEPS, adjusted EBITDA and adjusted EBITDA margin, Net Debt, CapEx, Free Cash Flow are non-GAAP financial measures. Please refer to slides 16 to 21 for a reconciliati
Slide 13: Franco Stevanato, Chairman & Chief Executive Officer
Franco Stevanato Chairman & Chief Executive Officer Q3 2025 Financial Results
Slide 14: Sustained Momentum Driven by Healthy Market Demand and Rise in Biologics
Q3 2025 Financial Results Sustained Momentum Driven by Healthy Market Demand and Rise in Biologics; Well Positioned for Long-term Profitable Growth Performance underscores the strength of our long-term strategy and business fundamentals Continued solid delivery: (i) growth in HVS, (ii) innovation in
Slide 15: Stevanato Group
Stevanato Group Q3 2025 Financial Results
Slide 16: Non-GAAP Financial Measures
This presentation contains non-GAAP financial measures. Please refer to the tables included in this presentation for a reconciliation of non-GAAP measures. Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency
Slide 17: Reconciliation of Non-GAAP Financial Measures (1/5)
Q3 2025 Financial Results Reconciliation of Non-GAAP Financial Measures (1/5) Reconciliation of EBITDA (Amounts in € millions) Calculation of Net Profit margin, Operating Profit Margin, Adjusted EBITDA Margin and Adjusted Operating Profit Margin (Amounts in € millions) Reconciliation of Revenue to C
Slide 18: Reconciliation of Non-GAAP Financial Measures (2/5)
Q3 2025 Financial Results Reconciliation of Non-GAAP Financial Measures (2/5) Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit, and Diluted EPS (Amounts in € millions, except per share data) (1) During the three and the nine months ended September 30, 2025,
Slide 19: Reconciliation of Non-GAAP Financial Measures (3/5)
Q3 2025 Financial Results Reconciliation of Non-GAAP Financial Measures (3/5) Capital Employed (Amounts in € millions)
Slide 20: Reconciliation of Non-GAAP Financial Measures (4/5)
Q3 2025 Financial Results Reconciliation of Non-GAAP Financial Measures (4/5) Net (Debt) / Net Cash (Amounts in € millions) Free Cash Flow (Amounts in € millions) CAPEX (Amounts in € millions)
Slide 21: Reconciliation of Non-GAAP Financial Measures (5/5)
Q3 2025 Financial Results Reconciliation of Non-GAAP Financial Measures (5/5) Reconciliation of 2025 Guidance* Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS (Amounts in € millions, except per share data) *Amounts may not add due to rounding